Argon neuroprotection in a non-human primate model of transient endovascular ischemic stroke.

Torrecilla, S. G.; Delbrel, A.; Giacomino, L.; Meunier, D.; Sein, J.; Renaud, L.; Brige, P.; Garrigue, P.; Hak, J. F.; Guillet, B.; Brunel, H.; Farjot, G.; Brochier, T.; Velly, L.

doi:10.1101/2024.01.24.577050

bioRxiv · 10.1101/2024.01.24.577050

Argon neuroprotection in a non-human primate model of transient endovascular ischemic stroke.

Torrecilla, S. G.·Delbrel, A.·Giacomino, L.·Meunier, D.·Sein, J.·Renaud, L.·Brige, P.·Garrigue, P.·Hak, J. F.·Guillet, B.·Brunel, H.·Farjot, G.·Brochier, T.·Velly, L.

View original source ↗Export metadata ↓

Abstract

BackgroundPrevious studies have demonstrated the efficacy of argon neuroprotection in rodent models of cerebral ischemia. The objective of the present study was to confirm a potential neuroprotective effect of argon in a non-human primate model of endovascular ischemic stroke as an essential step before considering the use of argon as a neuroprotective agent in humans. MethodsThirteen adult monkeys (Macaca mulatta) were allocated to two groups: a control group (n=8) without neuroprotection and an argon group (n=5) in which argon inhalation (90 min) was initiated 30 minutes after onset of ischemia. Animals in both groups underwent brain MRI (pre-ischemic) at least 7 days before the intervention. The monkeys were subjected to focal cerebral ischemia induced by a transient (90 min) middle cerebral artery occlusion (tMCAO). After tMCAO, MRI was performed 1 hour after cerebral reperfusion. The ischemic core volume was defined by the apparent diffusion coefficient (aDC) and edema in fluid attenuated inversion recovery (FLAIR) acquisitions. MRI masks were applied to distinguish between cortical and subcortical abnormalities. In addition, a modified version of the Rankin scale was used to neurologically assess post-tMCAO. ResultsDespite variability in the ischemic core and edema volumes in the control group, argon significantly reduced ischemic core volume after ischemia compared to the control group (1.1{+/-}1.6 cm3 vs. 8.5{+/-}8.1 cm3; p=0.03). This effect was limited to cortical structures (0.6{+/-}1.1 cm3 vs. 7.4{+/-}7.2 cm3; p=0.03). No significant differences were observed in the edema volumes. Measures of neurological clinical outcome suggested a better prognosis in argon-treated animals. ConclusionsIn the tMCAO macaque model, argon induced effective neuroprotective effects, leading to a reduced ischemic core in cortical areas. These results support the potential use of this therapeutic approach for future clinical studies in stroke patients.

Explore related subjects

neuroscience Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Torrecilla, S. G., Delbrel, A., Giacomino, L., Meunier, D., Sein, J., Renaud, L., Brige, P., Garrigue, P., Hak, J. F., Guillet, B., Brunel, H., Farjot, G., Brochier, T., Velly, L.. 2024-01-24. Argon neuroprotection in a non-human primate model of transient endovascular ischemic stroke.. https://doi.org/10.1101/2024.01.24.577050

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

bioRxiv2026

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

bioRxiv2026

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗